MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.

@article{Wijburg2016MRICD,
  title={MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.},
  author={Martijn T. Wijburg and Birgit I. Witte and Anke Vennegoor and S. D. Roosendaal and Esther Mar{\'i}a G{\'a}mez S{\'a}nchez and Yaou Liu and Carine O Martins Jarnalo and Bernard M. J. Uitdehaag and Frederik Barkhof and Joep Killestein and Mike P. Wattjes},
  journal={Journal of neurology, neurosurgery, and psychiatry},
  year={2016},
  volume={87 10},
  pages={
          1138-45
        }
}
OBJECTIVE Differentiation between progressive multifocal leukoencephalopathy (PML) and new multiple sclerosis (MS) lesions on brain MRI during natalizumab pharmacovigilance in the absence of clinical signs and symptoms is challenging but is of substantial clinical relevance. We aim to define MRI characteristics that can aid in this differentiation. METHODS Reference and follow-up brain MRIs of natalizumab-treated patients with MS with asymptomatic PML (n=21), or asymptomatic new MS lesions (n… CONTINUE READING
BETA
34
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

MRT-Veränderungen bei Immunmodulation

K Guggenberger, Horst Urbach
  • Der Nervenarzt
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 39 REFERENCES

MRI pattern in asymptomatic natalizumab-associated PML.

  • Journal of neurology, neurosurgery, and psychiatry
  • 2015

Similar Papers

Loading similar papers…